Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma

Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma

Abstract Objective To evaluate the effects of the concomitant use of proton pump inhibitors (PPIs) and/or antibiotics (Abs) on oncological outcomes in patients with advanced urothelial carcinoma. Patients and methods We retrospectively evaluated 155 patients with advanced urothelial carcinoma who we...

Full description

Bibliographic Details
Main Authors:	Yoshiharu Okuyama, Shingo Hatakeyama, Kazuyuki Numakura, Takuma Narita, Toshikazu Tanaka, Yuki Miura, Daichi Sasaki, Daisuke Noro, Noriko Tokui, Teppei Okamoto, Hayato Yamamoto, Shintaro Narita, Takahiro Yoneyama, Yasuhiro Hashimoto, Tomonori Habuchi, Chikara Ohyama
Format:	Article
Language:	English
Published:	Wiley 2022-03-01
Series:	BJUI Compass
Subjects:	antibiotics immune checkpoint inhibitors immunotherapy prognosis proton pump inhibitor urothelial carcinoma
Online Access:	https://doi.org/10.1002/bco2.118

Similar Items

The impact of eligibility for maintenance immunotherapy on prognosis in patients with unresectable or metastatic urothelial carcinoma
by: Kai Ozaki, et al.
Published: (2022-03-01)

Incidence, Etiology, Prevention and Management of Ureteroenteric Strictures after Robot-Assisted Radical Cystectomy: A Review of Published Evidence and Personal Experience
by: Shintaro Narita, et al.
Published: (2021-10-01)

Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas
by: Toshikazu Tanaka, et al.
Published: (2017-12-01)

Urothelial carcinoma: the evolving landscape of immunotherapy for patients with advanced disease
by: Dietrich B, et al.
Published: (2018-01-01)

Novel Tyrosine Kinase Targets in Urothelial Carcinoma
by: Javier Torres-Jiménez, et al.
Published: (2021-01-01)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018-01-01)

Novel immunotherapy in the management of advanced urothelial cancer - review of the literature
by: Paulina Chmiel, et al.
Published: (2022-08-01)

Metastatic Urothelial Carcinoma: Have We Take the Road to the Personalized Medicine?
by: Marco Audisio, et al.
Published: (2022-05-01)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
by: Tassinari E, et al.
Published: (2022-06-01)

Efficacy of pembrolizumab rechallenge for metastatic urothelial carcinoma
by: Nobutaka Nishimura, et al.
Published: (2022-09-01)

Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions
by: Yuki Endo, et al.
Published: (2024-01-01)

Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder
by: Sandra van Wilpe, et al.
Published: (2020-09-01)

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors
by: Jean-Michel Lavoie, et al.
Published: (2021-11-01)

Research Progress on the Effect of Clinical Concomitant Medication on Efficacy of Immune Checkpoint Inhibitors in Urothelial Carcinoma
by: LYU Zhengqin, et al.
Published: (2024-03-01)

Prognostic Factors of Platinum-Refractory Advanced Urothelial Carcinoma Treated with Pembrolizumab
by: Yasunori Akashi, et al.
Published: (2023-12-01)

Immunotherapy for Urothelial Carcinoma: Focus on Clinical Utility of Nivolumab
by: Chiang RS, et al.
Published: (2022-10-01)

Progress in immune checkpoint inhibitor-based combined regimens in the treatment of metastatic urothelial carcinoma
by: Liu Jianbing, Yue Zhongjin, Shang Panfeng, Liu Yating, Chang Hong
Published: (2023-09-01)

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
by: Lilong Zhang, et al.
Published: (2022-09-01)

Neoangiogenesis markers in canine urothelial carcinomas: A cross‐sectional study
by: Fabio Gentilini, et al.
Published: (2024-03-01)

Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation
by: Shibin Zhu, et al.
Published: (2022-10-01)

Management of Fibroblast Growth Factor Inhibitor Treatment–emergent Adverse Events of Interest in Patients with Locally Advanced or Metastatic Urothelial Carcinoma
by: Arlene O. Siefker-Radtke, et al.
Published: (2023-04-01)

Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
by: Li-Yu Yang, et al.
Published: (2024-03-01)

The efficacy and safety of chemotherapy with or without anti‐PD‐1 for the first‐line treatment of advanced urothelial carcinoma
by: Fuxin Han, et al.
Published: (2023-12-01)

Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
by: Tae Jin Kim, et al.
Published: (2020-01-01)

Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis
by: Alessandro Rizzo, et al.
Published: (2022-02-01)

Wnt/β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma
by: Alexander Chehrazi-Raffle, et al.
Published: (2021-02-01)

Complete response to pembrolizumab for metastatic urothelial carcinoma in the renal pelvis of allograft kidney
by: Jun Kamei, et al.
Published: (2022-05-01)

A comparison of nephrotoxicity between patients with a solitary-functioning kidney and those with bilateral-functioning kidneys in cisplatin-based chemotherapy for advanced urothelial carcinoma: a Japanese retrospective multi-institutional study
by: Takamitsu Inoue, et al.
Published: (2018-03-01)

Treatment Strategies and Metabolic Pathway Regulation in Urothelial Cell Carcinoma: A Comprehensive Review
by: Huang-Yu Yang, et al.
Published: (2020-11-01)

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
by: Utpal Kumar, et al.
Published: (2022-06-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
by: Inokuchi J, et al.
Published: (2019-05-01)

Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS)
by: P. Grivas, et al.
Published: (2021-05-01)

The prognostic value of PD‐L1 expression in upper tract urothelial carcinoma varies according to platelet count
by: Yu Miyama, et al.
Published: (2018-09-01)

PARP Inhibitors in Prostate and Urothelial Cancers
by: Rohan Garje, et al.
Published: (2020-02-01)

TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma
by: Elodie Coquan, et al.
Published: (2022-11-01)

Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials
by: Hsiao-Ling Chen, et al.
Published: (2021-03-01)

Neoadjuvant Immunotherapy: The Next Gold Standard Before Radical Surgery for Urothelial Cancer
by: Daniele Raggi, et al.
Published: (2021-08-01)

Efficacy and Safety of Programmed Death-1/Programmed Death-Ligand 1 Inhibitor for Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
by: Pei-Fei Liao, et al.
Published: (2023-11-01)

Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti–PD-1/PD-L1–Based Therapy
by: Haifeng Li, et al.
Published: (2021-08-01)

Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma
by: Veronica Mollica, et al.
Published: (2020-06-01)